U

Urteste SA
WSE:URT

Watchlist Manager
Urteste SA
WSE:URT
Watchlist
Price: 92 PLN 4.07% Market Closed
Market Cap: 129.7m PLN
Have any thoughts about
Urteste SA?
Write Note

Urteste SA
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Urteste SA
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
U
Urteste SA
WSE:URT
Total Liabilities & Equity
zł29.6m
CAGR 3-Years
250%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Total Liabilities & Equity
zł179.3m
CAGR 3-Years
-2%
CAGR 5-Years
11%
CAGR 10-Years
2%
R
Read Gene SA
WSE:RDG
Total Liabilities & Equity
zł11.3m
CAGR 3-Years
-11%
CAGR 5-Years
-6%
CAGR 10-Years
0%
G
Genomed SA
WSE:GEN
Total Liabilities & Equity
zł12.1m
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Total Liabilities & Equity
zł790.4m
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
-9%
S
Synthaverse SA
WSE:SVE
Total Liabilities & Equity
zł293.2m
CAGR 3-Years
38%
CAGR 5-Years
27%
CAGR 10-Years
10%
No Stocks Found

Urteste SA
Glance View

Market Cap
129.7m PLN
Industry
Biotechnology

Urteste SA specializes in the development of technology that allows the detection of cancers at early stages of their development. The company is headquartered in Gdansk, Woj. Pomorskie. The company went IPO on 2021-10-27. The firm operates in the field of medical devices for in vitro application in the field of cancer diagnostics. The technology developed by the Company involves the detection of cancer by measuring the activity of enzymes in a urine sample, using diagnostic tests that enable the detection of common cancers in their early stages. The firm offers tests for the detection of cancers such as, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, stomach cancer, esophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukemia, lymphoma, glioma.

URT Intrinsic Value
11.44 PLN
Overvaluation 88%
Intrinsic Value
Price
U

See Also

What is Urteste SA's Total Liabilities & Equity?
Total Liabilities & Equity
29.6m PLN

Based on the financial report for Dec 31, 2023, Urteste SA's Total Liabilities & Equity amounts to 29.6m PLN.

What is Urteste SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
250%

Over the last year, the Total Liabilities & Equity growth was 342%. The average annual Total Liabilities & Equity growth rates for Urteste SA have been 250% over the past three years .

Back to Top